46 results
CORRESP
SVA
Sinovac Biotech, Ltd.
10 Jul 23
Correspondence with SEC
12:00am
result in substantial costs and diversion of resources and management attention, negative publicity, damage to our reputation and decline in the price … as subject us to negative publicity in the future, which could harm our reputation and negatively affect the value of our shares and/or other
6-K
EX-99.2
9kr f3tq69
3 Jul 18
Current report (foreign)
9:01am
424B5
818nb
28 Jan 10
Prospectus supplement for primary offering
12:00am
424B5
v477fk 3dmixv
20 Jan 10
Prospectus supplement for primary offering
12:00am